|Awarded On||February 18, 2015|
|Title||Tumor Cell Epithelial-Mesenchymal Transition in Regulating Immunosuppression and Metastasis in Lung Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Don Gibbons|
|Cancer Sites||Lung and Bronchus|
Lung cancer is an aggressive metastatic cancer that claims 160000 lives in the US annually. Our long-term goal is to develop prevention and treatment strategies for metastasis, to ultimately improve cure rates. To this end, we have been investigating immune therapy. Lung cancer cells recruit and activate diverse inflammatory cells, creating an immunosuppressive environment favoring tumor growth and spread. We have developed genetic mouse models with the mutations found in human lung cancer for detailed study of the determinants of metastasis. We found that metastatic cancer cells specifically turn off killer T cells by expression of a molecule on their surface, called programmed death ligand...